McGuan v. Endovascular Technologies
The Food and Drug Administration (FDA) approved the ANCURE ENDOGRAFT System (Ancure Device) for use by surgeons to treat abdominal aortic aneurysms. Plaintiffs Michael J. McGuan and Lillian Johnson, who suffered severe injuries after they were implanted with this device, brought products liability and personal injury actions against defendants Endovascular Technologies, Inc. (EVT), Guidant Corporation (Guidant), Advanced Cardiovascular Systems, Inc., and Origin Medsystems, Inc.[1] The trial court granted defendants motions for summary judgment on the ground that plaintiffs claims were preempted by federal law. The trial court also denied plaintiffs motions to amend their complaints, and granted defendants motions to seal portions of the record. Plaintiffs have filed timely appeals from the judgments of dismissal. For the reasons stated below, Court affirm.
Comments on McGuan v. Endovascular Technologies